Related Experiment Videos
New therapeutic agents in the treatment of recurrent high-grade gliomas
1Divisione di Oncologia Medica, Azienda Ospedale, Universit di Padova, Padova, Italy.
Abstract:
The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration. This article analyses the new drugs that have been introduced in the treatment of these patients in the latest years, the objective response, the time to progression and the mean survival time. The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years. New approaches to the chemotherapy treatment are necessary. Enrolment of patients into rigorous, well-conducted, clinical trials, both at tumour diagnosis and after tumour recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.
Insights
New chemotherapy drugs offer improved outcomes for patients with recurrent central nervous system (CNS) tumors. Temozolomide shows promising results, but further clinical trials are essential for advancing malignant glioma treatment.
Area of Science:
- Neuro-oncology
- Medical Chemistry
Background:
- Central nervous system (CNS) neoplasias affect 3.8-5.1 per 100,000 people.
- Recurrent CNS tumors present significant treatment challenges with limited chemotherapy efficacy.
Purpose of the Study:
- To analyze novel chemotherapy drugs for CNS neoplasias.
- To evaluate objective response, time to progression, and survival in patients with recurrent tumors.
Main Methods:
- Review of recent pharmacological advancements in CNS tumor chemotherapy.
- Analysis of clinical data on drug efficacy and tolerability.
Main Results:
- Temozolomide demonstrates encouraging activity and good tolerability in recent studies.
- Current chemotherapy responses are often palliative and short-lived.
Conclusions:
- New chemotherapy approaches are crucial for managing malignant gliomas.
- Enrollment in clinical trials is vital for developing improved investigational therapies.